Virpax Pharmaceuticals Faces Delisting Concerns
| Field | Detail |
|---|---|
| Company | Virpax Pharmaceuticals, Inc. |
| Form Type | 8-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, corporate-governance
TL;DR
Virpax might get delisted, major shakeup incoming.
AI Summary
Virpax Pharmaceuticals, Inc. filed an 8-K on April 3, 2025, reporting a notice of delisting or failure to meet continued listing standards. The filing also covers the departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. Additionally, it includes financial statements and exhibits.
Why It Matters
This filing indicates potential issues with Virpax Pharmaceuticals' ability to remain listed on an exchange, which could significantly impact its stock value and access to capital.
Risk Assessment
Risk Level: high — The filing explicitly mentions a notice of delisting or failure to satisfy continued listing rules, indicating significant financial or operational distress.
Key Players & Entities
- Virpax Pharmaceuticals, Inc. (company) — Registrant
- 001-40064 (company) — SEC File Number
- 82-1510982 (company) — I.R.S. Employer Identification No.
FAQ
What specific listing rule or standard has Virpax Pharmaceuticals failed to meet?
The filing does not specify the exact rule or standard that Virpax Pharmaceuticals has failed to meet, only that a notice has been issued.
When was the notice of delisting or failure to meet listing standards issued?
The earliest event reported in the filing is dated April 2, 2025, and the filing was made on April 3, 2025.
Are there any details provided about the departure of directors or officers?
The filing indicates that the departure of directors or certain officers is an item being reported, but specific names or reasons are not detailed in the provided text.
What is the company's primary business sector?
Virpax Pharmaceuticals, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
What is the company's principal executive office address?
The company's business address is 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Virpax Pharmaceuticals, Inc..